Literature DB >> 31144293

α7 nicotinic ACh receptors are necessary for memory recovery and neuroprotection promoted by attention training in amyloid-β-infused mice.

Milena Telles-Longui1, Danilo Mourelle1, Natalia Mendes Schöwe1,2, Gabriela Cabett Cipolli3, Helena Nascimento Malerba1,2, Hudson Sousa Buck4,2, Tania Araujo Viel1,3.   

Abstract

BACKGROUND AND
PURPOSE: Attention training reverses the neurodegeneration and memory loss promoted by infusion of amyloid-β (Aβ) peptide in rats and increases the density of α7 nicotinic ACh receptors (α7nAChRs) in brain areas related to memory. Hence, we aimed to assess the role of α7nAChRs in the memory recovery promoted by attention training. EXPERIMENTAL APPROACH: C57Bl/6 mice were chronically infused with Aβ, Aβ plus the α7 antagonist methyllycaconitine (MLA), or MLA alone. Control animals were infused with vehicle. Animals were subjected weekly to the active avoidance shuttle box for 4 weeks (attention training). The brain and serum were collected for biochemical and histological analysis. KEY
RESULTS: Aβ caused cognitive impairment, which was reversed by the weekly training, whereas Aβ + MLA also promoted memory loss but with no reversal with weekly training. MLA alone also promoted memory loss but with only partial reversal with the training. Animals infused with Aβ alone showed senile plaques in hippocampus, no change in BDNF levels in cortex, hippocampus, and serum, but increased AChE activity in cortex and hippocampus. Co-treatment with MLA increased AChE activity and senile plaque deposition in hippocampus as well as reducing BDNF in hippocampus and serum, suggesting a lack of α7nAChR function leads to a loss of neuroprotection mechanisms. CONCLUSIONS AND IMPLICATIONS: The α7nAChR has a determinant role in memory recovery and brain resilience in the presence of neurodegeneration promoted by Aβ peptide. These data support further studies concerning these receptors as pharmacological targets for future therapies.
© 2019 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31144293      PMCID: PMC6692581          DOI: 10.1111/bph.14744

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  73 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 2.  Effects of environmental enrichment exposure on synaptic transmission and plasticity in the hippocampus.

Authors:  Michael J Eckert; Wickliffe C Abraham
Journal:  Curr Top Behav Neurosci       Date:  2013

Review 3.  Alzheimer's disease.

Authors:  Philip Scheltens; Kaj Blennow; Monique M B Breteler; Bart de Strooper; Giovanni B Frisoni; Stephen Salloway; Wiesje Maria Van der Flier
Journal:  Lancet       Date:  2016-02-24       Impact factor: 79.321

Review 4.  Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease.

Authors:  Dietmar Rudolf Thal; Jochen Walter; Takaomi C Saido; Marcus Fändrich
Journal:  Acta Neuropathol       Date:  2014-12-23       Impact factor: 17.088

Review 5.  Cognitive reserve in ageing and Alzheimer's disease.

Authors:  Yaakov Stern
Journal:  Lancet Neurol       Date:  2012-11       Impact factor: 44.182

6.  Participation of hippocampal nicotinic receptors in acquisition, consolidation and retrieval of memory for one trial inhibitory avoidance in rats.

Authors:  D Martí Barros; M R Ramirez; E A Dos Reis; I Izquierdo
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

7.  Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease.

Authors:  Allam A Rao; Gumpeny R Sridhar; Undurti N Das
Journal:  Med Hypotheses       Date:  2007-06-05       Impact factor: 1.538

8.  A sensitive technique for the detection of the alpha 7 neuronal nicotinic acetylcholine receptor antagonist, methyllycaconitine, in rat plasma and brain.

Authors:  J W Turek; C H Kang; J E Campbell; S P Arneric; J P Sullivan
Journal:  J Neurosci Methods       Date:  1995 Sep-Oct       Impact factor: 2.390

Review 9.  Cognitive control, cognitive reserve, and memory in the aging bilingual brain.

Authors:  Angela Grant; Nancy A Dennis; Ping Li
Journal:  Front Psychol       Date:  2014-12-03

10.  Neuroprotective Effects of Pomegranate Peel Extract after Chronic Infusion with Amyloid-β Peptide in Mice.

Authors:  Maressa Caldeira Morzelle; Jocelem Mastrodi Salgado; Milena Telles; Danilo Mourelle; Patricia Bachiega; Hudson Sousa Buck; Tania Araujo Viel
Journal:  PLoS One       Date:  2016-11-09       Impact factor: 3.240

View more
  4 in total

1.  α7 nicotinic ACh receptors are necessary for memory recovery and neuroprotection promoted by attention training in amyloid-β-infused mice.

Authors:  Milena Telles-Longui; Danilo Mourelle; Natalia Mendes Schöwe; Gabriela Cabett Cipolli; Helena Nascimento Malerba; Hudson Sousa Buck; Tania Araujo Viel
Journal:  Br J Pharmacol       Date:  2019-07-14       Impact factor: 8.739

2.  α7 Nicotinic Acetylcholine Receptor May Be a Pharmacological Target for Perioperative Neurocognitive Disorders.

Authors:  Penghui Wei; Wenyuan Lyu; Lin Xu; Hao Feng; Haipeng Zhou; Jianjun Li
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

Review 3.  Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer's Disease and Future Perspectives.

Authors:  Natália Chermont Dos Santos Moreira; Jéssica Ellen Barbosa de Freitas Lima; Marcelo Fiori Marchiori; Ivone Carvalho; Elza Tiemi Sakamoto-Hojo
Journal:  J Alzheimers Dis Rep       Date:  2022-04-18

4.  Mechanisms of neuroplasticity and brain degeneration: strategies for protection during the aging process.

Authors:  Mariana Toricelli; Arthur Antonio Ruiz Pereira; Guilherme Souza Abrao; Helena Nascimento Malerba; Julia Maia; Hudson Sousa Buck; Tania Araujo Viel
Journal:  Neural Regen Res       Date:  2021-01       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.